Abstract
Aims. This study aimed to quantify the prevalence of frailty, and investigate the impact of frailty on adverse outcomes, in older patients with cancer in Vietnam. Methods. A prospective, observational study was conducted in adults aged 65 or above with cancer who attended the outpatient clinics of two urban hospitals in Vietnam from September 2023 to May 2024. Frailty was defined by the Carolina Frailty Index (CFI) and participants with a CFI >0.35 were identified as frail. All participants were followed up for 3 months after discharge, recording falls, all cause hospitalization, and all cause mortality. Results. There were 379 participants (mean age 72.3 years, 48.5% female). The prevalence of frailty was 26.6% (95%CI 22.2% to 31.0%), highest in participants with stomach cancer (35.7%) and lung cancer (33.9%). Participants with advanced stages of cancer had a significantly higher prevalence of frailty: 39.3% in stage 4, 21.7% in stage 3, compared to 18.1% in stage 2 and 13.0% in stage 1. During the follow up, 19.0% of the participants had a fall (44.4% in the frail vs. 9.7% in the nonfrail, p<0.001), 33.4% were admitted to hospitals (42.2% in the frail vs. 30.1% in the nonfrail, p=0.026). The mortality rate was 1.9% (5.1% in the frail vs. 0.7% in the nonfrail, p=0.017). Odds ratios were 7.48 (95%CI 4.24 to 13.40, p<0.001) for falls, 1.71 (95%CI 1.06 to 2.75, p=0.027) for all cause hospitalization, and 7.10 (95%CI 1.36 to 37.22, p=0.020) for all cause mortality. Conclusion. Frailty was observed in over a quarter of the participants, with the highest prevalence among those with stomach and lung cancer. Frailty significantly increased the odds of falls, hospitalization, and mortality in three months post discharge. Further research is needed to gain a better understanding of the impact of frailty on adverse outcomes, and the quality of life for older adults with cancer in Vietnam.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Ethics Committee of the University of Medicine and Pharmacy at Ho Chi Minh City (Reference Number 676/HDDD-DHYD).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos